 | • レポートコード：MRC2-11QY11231 • 出版社/出版日：QYResearch / 2020年11月25日 ※2024年版があります。お問い合わせください。 • レポート形態：英文、PDF、90ページ • 納品方法：Eメール（納期：2~3日） • 産業分類：医療機器・消耗品 |
| Single User | ￥577,200 (USD3,900) | ▷ お問い合わせ |
| Multi User | ￥865,800 (USD5,850) | ▷ お問い合わせ |
| Enterprise License | ￥1,154,400 (USD7,800) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 当調査資料はがん分子バイオマーカーのグローバル市場について調査・分析したレポートです。種類別（遺伝的手法、タンパク質手法、イメージング）市場規模、用途別（製薬会社、医療研究所、病院）市場規模、地域別（北米、米国、カナダ、ヨーロッパ、ドイツ、フランス、イギリス、イタリア、ロシア、アジア、日本、中国、韓国、インド、オーストラリア、台湾、中南米、メキシコ、ブラジル、アルゼンチン、中東・アフリカ、トルコ、サウジアラビア、UAE等）市場規模データ、主な企業情報と企業別市場シェア等が収録されています。 ・調査範囲 ・エグゼクティブサマリー ・企業別がん分子バイオマーカーの競争状況、市場シェア ・世界のがん分子バイオマーカー市場：種類別市場規模 2015年-2020年（遺伝的手法、タンパク質手法、イメージング） ・世界のがん分子バイオマーカー市場：種類別市場規模予測 2021年-2026年（遺伝的手法、タンパク質手法、イメージング） ・世界のがん分子バイオマーカー市場：用途別市場規模 2015年-2020年（製薬会社、医療研究所、病院） ・世界のがん分子バイオマーカー市場：用途別市場規模予測 2021年-2026年（製薬会社、医療研究所、病院） ・北米のがん分子バイオマーカー市場分析：米国、カナダ ・ヨーロッパのがん分子バイオマーカー市場分析：ドイツ、フランス、イギリス、イタリア、ロシア等 ・アジアのがん分子バイオマーカー市場分析：日本、中国、韓国、インド、オーストラリア、台湾等 ・中南米のがん分子バイオマーカー市場分析：メキシコ、ブラジル、アルゼンチン等 ・中東・アフリカのがん分子バイオマーカー市場分析：トルコ、サウジアラビア、UAE等 ・企業情報（企業概要、製品概要、販売量、企業動向） - 掲載企業（変更可能性あり）：Correlogic Systems、AgendiaBv、BioMerieux、Aureon Laboratories、Astellas Pharma US、Becton、Diadexus、Abbott Laboratories、Affymetrix、Clarient、Biomoda、Beckman Coulter、Dickinson ・地域別市場規模予測（2021年-2026年）：北米市場、ヨーロッパ市場、アジア市場、中南米市場、中東・アフリカ市場 ・市場機会、課題、リスク、環境分析 ・バリューチェーン、販売チャネル分析 ・調査の結論 |
Cancer molecular biomarkers refer to naturally-occurring molecules or genes in living organisms, which is an indicator for the presence of cancer in the body.A biomarker is a measurable indicator of biological process, condition, or disease and can be found in the blood, tissues, or other body fluids. Cancer molecular biomarkers help to diagnose cancer and monitor patients’ responses to treatments.
Factors such as technological advancements, increasing research and development activities, increase in funding from various government and non-government organizations, rise in healthcare expenditure, non invasive technology, increasing incidences of cancer, and streamlined drug delivery process are expected to drive the market for cancer molecular biomarkers .In addition, growing survival rates and increased accuracy of diagnosis with the help of biomarkers are expected to drive market for cancer molecular biomarkers.
Market Analysis and Insights: Global Cancer Molecular Biomarkers Market
The global Cancer Molecular Biomarkers market size is projected to reach US$ XX million by 2026, from US$ XX million in 2020, at a CAGR of XX%% during 2021-2026.
Global Cancer Molecular Biomarkers Scope and Market Size
Cancer Molecular Biomarkers market is segmented by Type, and by Application. Players, stakeholders, and other participants in the global Cancer Molecular Biomarkers market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2015-2026.
The key players covered in this study
Correlogic Systems
AgendiaBv
BioMerieux
Aureon Laboratories
Astellas Pharma US
Becton
Diadexus
Abbott Laboratories
Affymetrix
Clarient
Biomoda
Beckman Coulter
Dickinson
Market segment by Type, the product can be split into
Genetic Methods
Protein Methods
Imaging
Market segment by Application, split into
Pharmaceutical Companies
Medical Laboratory
Hospital
Market segment by Regions/Countries, this report covers
North America
Europe
China
Japan
Southeast Asia
India
1 Report Overview
1.1 Study Scope
1.2 Key Market Segments
1.3 Players Covered: Ranking by Cancer Molecular Biomarkers Revenue
1.4 Market by Type
1.4.1 Global Cancer Molecular Biomarkers Market Size Growth Rate by Type: 2020 VS 2026
1.4.2 Genetic Methods
1.4.3 Protein Methods
1.4.4 Imaging
1.5 Market by Application
1.5.1 Global Cancer Molecular Biomarkers Market Share by Application: 2020 VS 2026
1.5.2 Pharmaceutical Companies
1.5.3 Medical Laboratory
1.5.4 Hospital
1.6 Study Objectives
1.7 Years Considered
2 Global Growth Trends
2.1 Global Cancer Molecular Biomarkers Market Perspective (2015-2026)
2.2 Global Cancer Molecular Biomarkers Growth Trends by Regions
2.2.1 Cancer Molecular Biomarkers Market Size by Regions: 2015 VS 2020 VS 2026
2.2.2 Cancer Molecular Biomarkers Historic Market Share by Regions (2015-2020)
2.2.3 Cancer Molecular Biomarkers Forecasted Market Size by Regions (2021-2026)
2.3 Industry Trends and Growth Strategy
2.3.1 Market Top Trends
2.3.2 Market Drivers
2.3.3 Market Challenges
2.3.4 Porter’s Five Forces Analysis
2.3.5 Cancer Molecular Biomarkers Market Growth Strategy
2.3.6 Primary Interviews with Key Cancer Molecular Biomarkers Players (Opinion Leaders)
3 Competition Landscape by Key Players
3.1 Global Top Cancer Molecular Biomarkers Players by Market Size
3.1.1 Global Top Cancer Molecular Biomarkers Players by Revenue (2015-2020)
3.1.2 Global Cancer Molecular Biomarkers Revenue Market Share by Players (2015-2020)
3.1.3 Global Cancer Molecular Biomarkers Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.2 Global Cancer Molecular Biomarkers Market Concentration Ratio
3.2.1 Global Cancer Molecular Biomarkers Market Concentration Ratio (CR5 and HHI)
3.2.2 Global Top 10 and Top 5 Companies by Cancer Molecular Biomarkers Revenue in 2019
3.3 Cancer Molecular Biomarkers Key Players Head office and Area Served
3.4 Key Players Cancer Molecular Biomarkers Product Solution and Service
3.5 Date of Enter into Cancer Molecular Biomarkers Market
3.6 Mergers & Acquisitions, Expansion Plans
4 Market Size by Type (2015-2026)
4.1 Global Cancer Molecular Biomarkers Historic Market Size by Type (2015-2020)
4.2 Global Cancer Molecular Biomarkers Forecasted Market Size by Type (2021-2026)
5 Market Size by Application (2015-2026)
5.1 Global Cancer Molecular Biomarkers Market Size by Application (2015-2020)
5.2 Global Cancer Molecular Biomarkers Forecasted Market Size by Application (2021-2026)
6 North America
6.1 North America Cancer Molecular Biomarkers Market Size (2015-2020)
6.2 Cancer Molecular Biomarkers Key Players in North America (2019-2020)
6.3 North America Cancer Molecular Biomarkers Market Size by Type (2015-2020)
6.4 North America Cancer Molecular Biomarkers Market Size by Application (2015-2020)
7 Europe
7.1 Europe Cancer Molecular Biomarkers Market Size (2015-2020)
7.2 Cancer Molecular Biomarkers Key Players in Europe (2019-2020)
7.3 Europe Cancer Molecular Biomarkers Market Size by Type (2015-2020)
7.4 Europe Cancer Molecular Biomarkers Market Size by Application (2015-2020)
8 China
8.1 China Cancer Molecular Biomarkers Market Size (2015-2020)
8.2 Cancer Molecular Biomarkers Key Players in China (2019-2020)
8.3 China Cancer Molecular Biomarkers Market Size by Type (2015-2020)
8.4 China Cancer Molecular Biomarkers Market Size by Application (2015-2020)
9 Japan
9.1 Japan Cancer Molecular Biomarkers Market Size (2015-2020)
9.2 Cancer Molecular Biomarkers Key Players in Japan (2019-2020)
9.3 Japan Cancer Molecular Biomarkers Market Size by Type (2015-2020)
9.4 Japan Cancer Molecular Biomarkers Market Size by Application (2015-2020)
10 Southeast Asia
10.1 Southeast Asia Cancer Molecular Biomarkers Market Size (2015-2020)
10.2 Cancer Molecular Biomarkers Key Players in Southeast Asia (2019-2020)
10.3 Southeast Asia Cancer Molecular Biomarkers Market Size by Type (2015-2020)
10.4 Southeast Asia Cancer Molecular Biomarkers Market Size by Application (2015-2020)
11 India
11.1 India Cancer Molecular Biomarkers Market Size (2015-2020)
11.2 Cancer Molecular Biomarkers Key Players in India (2019-2020)
11.3 India Cancer Molecular Biomarkers Market Size by Type (2015-2020)
11.4 India Cancer Molecular Biomarkers Market Size by Application (2015-2020)
12 Central & South America
12.1 Central & South America Cancer Molecular Biomarkers Market Size (2015-2020)
12.2 Cancer Molecular Biomarkers Key Players in Central & South America (2019-2020)
12.3 Central & South America Cancer Molecular Biomarkers Market Size by Type (2015-2020)
12.4 Central & South America Cancer Molecular Biomarkers Market Size by Application (2015-2020)
13 Key Players Profiles
13.1 Correlogic Systems
13.1.1 Correlogic Systems Company Details
13.1.2 Correlogic Systems Business Overview
13.1.3 Correlogic Systems Cancer Molecular Biomarkers Introduction
13.1.4 Correlogic Systems Revenue in Cancer Molecular Biomarkers Business (2015-2020))
13.1.5 Correlogic Systems Recent Development
13.2 AgendiaBv
13.2.1 AgendiaBv Company Details
13.2.2 AgendiaBv Business Overview
13.2.3 AgendiaBv Cancer Molecular Biomarkers Introduction
13.2.4 AgendiaBv Revenue in Cancer Molecular Biomarkers Business (2015-2020)
13.2.5 AgendiaBv Recent Development
13.3 BioMerieux
13.3.1 BioMerieux Company Details
13.3.2 BioMerieux Business Overview
13.3.3 BioMerieux Cancer Molecular Biomarkers Introduction
13.3.4 BioMerieux Revenue in Cancer Molecular Biomarkers Business (2015-2020)
13.3.5 BioMerieux Recent Development
13.4 Aureon Laboratories
13.4.1 Aureon Laboratories Company Details
13.4.2 Aureon Laboratories Business Overview
13.4.3 Aureon Laboratories Cancer Molecular Biomarkers Introduction
13.4.4 Aureon Laboratories Revenue in Cancer Molecular Biomarkers Business (2015-2020)
13.4.5 Aureon Laboratories Recent Development
13.5 Astellas Pharma US
13.5.1 Astellas Pharma US Company Details
13.5.2 Astellas Pharma US Business Overview
13.5.3 Astellas Pharma US Cancer Molecular Biomarkers Introduction
13.5.4 Astellas Pharma US Revenue in Cancer Molecular Biomarkers Business (2015-2020)
13.5.5 Astellas Pharma US Recent Development
13.6 Becton
13.6.1 Becton Company Details
13.6.2 Becton Business Overview
13.6.3 Becton Cancer Molecular Biomarkers Introduction
13.6.4 Becton Revenue in Cancer Molecular Biomarkers Business (2015-2020)
13.6.5 Becton Recent Development
13.7 Diadexus
13.7.1 Diadexus Company Details
13.7.2 Diadexus Business Overview
13.7.3 Diadexus Cancer Molecular Biomarkers Introduction
13.7.4 Diadexus Revenue in Cancer Molecular Biomarkers Business (2015-2020)
13.7.5 Diadexus Recent Development
13.8 Abbott Laboratories
13.8.1 Abbott Laboratories Company Details
13.8.2 Abbott Laboratories Business Overview
13.8.3 Abbott Laboratories Cancer Molecular Biomarkers Introduction
13.8.4 Abbott Laboratories Revenue in Cancer Molecular Biomarkers Business (2015-2020)
13.8.5 Abbott Laboratories Recent Development
13.9 Affymetrix
13.9.1 Affymetrix Company Details
13.9.2 Affymetrix Business Overview
13.9.3 Affymetrix Cancer Molecular Biomarkers Introduction
13.9.4 Affymetrix Revenue in Cancer Molecular Biomarkers Business (2015-2020)
13.9.5 Affymetrix Recent Development
13.10 Clarient
13.10.1 Clarient Company Details
13.10.2 Clarient Business Overview
13.10.3 Clarient Cancer Molecular Biomarkers Introduction
13.10.4 Clarient Revenue in Cancer Molecular Biomarkers Business (2015-2020)
13.10.5 Clarient Recent Development
13.11 Biomoda
10.11.1 Biomoda Company Details
10.11.2 Biomoda Business Overview
10.11.3 Biomoda Cancer Molecular Biomarkers Introduction
10.11.4 Biomoda Revenue in Cancer Molecular Biomarkers Business (2015-2020)
10.11.5 Biomoda Recent Development
13.12 Beckman Coulter
10.12.1 Beckman Coulter Company Details
10.12.2 Beckman Coulter Business Overview
10.12.3 Beckman Coulter Cancer Molecular Biomarkers Introduction
10.12.4 Beckman Coulter Revenue in Cancer Molecular Biomarkers Business (2015-2020)
10.12.5 Beckman Coulter Recent Development
13.13 Dickinson
10.13.1 Dickinson Company Details
10.13.2 Dickinson Business Overview
10.13.3 Dickinson Cancer Molecular Biomarkers Introduction
10.13.4 Dickinson Revenue in Cancer Molecular Biomarkers Business (2015-2020)
10.13.5 Dickinson Recent Development
14 Analyst’s Viewpoints/Conclusions
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.2 Data Source
15.2 Disclaimer
15.3 Author Details
Table 1. Cancer Molecular Biomarkers Key Market Segments
Table 2. Key Players Covered: Ranking by Cancer Molecular Biomarkers Revenue
Table 3. Ranking of Global Top Cancer Molecular Biomarkers Manufacturers by Revenue (US$ Million) in 2019
Table 4. Global Cancer Molecular Biomarkers Market Size Growth Rate by Type (US$ Million): 2020 VS 2026
Table 5. Key Players of Genetic Methods
Table 6. Key Players of Protein Methods
Table 7. Key Players of Imaging
Table 8. Global Cancer Molecular Biomarkers Market Size Growth by Application (US$ Million): 2020 VS 2026
Table 9. Global Cancer Molecular Biomarkers Market Size by Regions (US$ Million): 2020 VS 2026
Table 10. Global Cancer Molecular Biomarkers Market Size by Regions (2015-2020) (US$ Million)
Table 11. Global Cancer Molecular Biomarkers Market Share by Regions (2015-2020)
Table 12. Global Cancer Molecular Biomarkers Forecasted Market Size by Regions (2021-2026) (US$ Million)
Table 13. Global Cancer Molecular Biomarkers Market Share by Regions (2021-2026)
Table 14. Market Top Trends
Table 15. Key Drivers: Impact Analysis
Table 16. Key Challenges
Table 17. Cancer Molecular Biomarkers Market Growth Strategy
Table 18. Main Points Interviewed from Key Cancer Molecular Biomarkers Players
Table 19. Global Cancer Molecular Biomarkers Revenue by Players (2015-2020) (Million US$)
Table 20. Global Cancer Molecular Biomarkers Market Share by Players (2015-2020)
Table 21. Global Top Cancer Molecular Biomarkers Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Cancer Molecular Biomarkers as of 2019)
Table 22. Global Cancer Molecular Biomarkers by Players Market Concentration Ratio (CR5 and HHI)
Table 23. Key Players Headquarters and Area Served
Table 24. Key Players Cancer Molecular Biomarkers Product Solution and Service
Table 25. Date of Enter into Cancer Molecular Biomarkers Market
Table 26. Mergers & Acquisitions, Expansion Plans
Table 27. Global Cancer Molecular Biomarkers Market Size by Type (2015-2020) (Million US$)
Table 28. Global Cancer Molecular Biomarkers Market Size Share by Type (2015-2020)
Table 29. Global Cancer Molecular Biomarkers Revenue Market Share by Type (2021-2026)
Table 30. Global Cancer Molecular Biomarkers Market Size Share by Application (2015-2020)
Table 31. Global Cancer Molecular Biomarkers Market Size by Application (2015-2020) (Million US$)
Table 32. Global Cancer Molecular Biomarkers Market Size Share by Application (2021-2026)
Table 33. North America Key Players Cancer Molecular Biomarkers Revenue (2019-2020) (Million US$)
Table 34. North America Key Players Cancer Molecular Biomarkers Market Share (2019-2020)
Table 35. North America Cancer Molecular Biomarkers Market Size by Type (2015-2020) (Million US$)
Table 36. North America Cancer Molecular Biomarkers Market Share by Type (2015-2020)
Table 37. North America Cancer Molecular Biomarkers Market Size by Application (2015-2020) (Million US$)
Table 38. North America Cancer Molecular Biomarkers Market Share by Application (2015-2020)
Table 39. Europe Key Players Cancer Molecular Biomarkers Revenue (2019-2020) (Million US$)
Table 40. Europe Key Players Cancer Molecular Biomarkers Market Share (2019-2020)
Table 41. Europe Cancer Molecular Biomarkers Market Size by Type (2015-2020) (Million US$)
Table 42. Europe Cancer Molecular Biomarkers Market Share by Type (2015-2020)
Table 43. Europe Cancer Molecular Biomarkers Market Size by Application (2015-2020) (Million US$)
Table 44. Europe Cancer Molecular Biomarkers Market Share by Application (2015-2020)
Table 45. China Key Players Cancer Molecular Biomarkers Revenue (2019-2020) (Million US$)
Table 46. China Key Players Cancer Molecular Biomarkers Market Share (2019-2020)
Table 47. China Cancer Molecular Biomarkers Market Size by Type (2015-2020) (Million US$)
Table 48. China Cancer Molecular Biomarkers Market Share by Type (2015-2020)
Table 49. China Cancer Molecular Biomarkers Market Size by Application (2015-2020) (Million US$)
Table 50. China Cancer Molecular Biomarkers Market Share by Application (2015-2020)
Table 51. Japan Key Players Cancer Molecular Biomarkers Revenue (2019-2020) (Million US$)
Table 52. Japan Key Players Cancer Molecular Biomarkers Market Share (2019-2020)
Table 53. Japan Cancer Molecular Biomarkers Market Size by Type (2015-2020) (Million US$)
Table 54. Japan Cancer Molecular Biomarkers Market Share by Type (2015-2020)
Table 55. Japan Cancer Molecular Biomarkers Market Size by Application (2015-2020) (Million US$)
Table 56. Japan Cancer Molecular Biomarkers Market Share by Application (2015-2020)
Table 57. Southeast Asia Key Players Cancer Molecular Biomarkers Revenue (2019-2020) (Million US$)
Table 58. Southeast Asia Key Players Cancer Molecular Biomarkers Market Share (2019-2020)
Table 59. Southeast Asia Cancer Molecular Biomarkers Market Size by Type (2015-2020) (Million US$)
Table 60. Southeast Asia Cancer Molecular Biomarkers Market Share by Type (2015-2020)
Table 61. Southeast Asia Cancer Molecular Biomarkers Market Size by Application (2015-2020) (Million US$)
Table 62. Southeast Asia Cancer Molecular Biomarkers Market Share by Application (2015-2020)
Table 63. India Key Players Cancer Molecular Biomarkers Revenue (2019-2020) (Million US$)
Table 64. India Key Players Cancer Molecular Biomarkers Market Share (2019-2020)
Table 65. India Cancer Molecular Biomarkers Market Size by Type (2015-2020) (Million US$)
Table 66. India Cancer Molecular Biomarkers Market Share by Type (2015-2020)
Table 67. India Cancer Molecular Biomarkers Market Size by Application (2015-2020) (Million US$)
Table 68. India Cancer Molecular Biomarkers Market Share by Application (2015-2020)
Table 69. Central & South America Key Players Cancer Molecular Biomarkers Revenue (2019-2020) (Million US$)
Table 70. Central & South America Key Players Cancer Molecular Biomarkers Market Share (2019-2020)
Table 71. Central & South America Cancer Molecular Biomarkers Market Size by Type (2015-2020) (Million US$)
Table 72. Central & South America Cancer Molecular Biomarkers Market Share by Type (2015-2020)
Table 73. Central & South America Cancer Molecular Biomarkers Market Size by Application (2015-2020) (Million US$)
Table 74. Central & South America Cancer Molecular Biomarkers Market Share by Application (2015-2020)
Table 75. Correlogic Systems Company Details
Table 76. Correlogic Systems Business Overview
Table 77. Correlogic Systems Product
Table 78. Correlogic Systems Revenue in Cancer Molecular Biomarkers Business (2015-2020) (Million US$)
Table 79. Correlogic Systems Recent Development
Table 80. AgendiaBv Company Details
Table 81. AgendiaBv Business Overview
Table 82. AgendiaBv Product
Table 83. AgendiaBv Revenue in Cancer Molecular Biomarkers Business (2015-2020) (Million US$)
Table 84. AgendiaBv Recent Development
Table 85. BioMerieux Company Details
Table 86. BioMerieux Business Overview
Table 87. BioMerieux Product
Table 88. BioMerieux Revenue in Cancer Molecular Biomarkers Business (2015-2020) (Million US$)
Table 89. BioMerieux Recent Development
Table 90. Aureon Laboratories Company Details
Table 91. Aureon Laboratories Business Overview
Table 92. Aureon Laboratories Product
Table 93. Aureon Laboratories Revenue in Cancer Molecular Biomarkers Business (2015-2020) (Million US$)
Table 94. Aureon Laboratories Recent Development
Table 95. Astellas Pharma US Company Details
Table 96. Astellas Pharma US Business Overview
Table 97. Astellas Pharma US Product
Table 98. Astellas Pharma US Revenue in Cancer Molecular Biomarkers Business (2015-2020) (Million US$)
Table 99. Astellas Pharma US Recent Development
Table 100. Becton Company Details
Table 101. Becton Business Overview
Table 102. Becton Product
Table 103. Becton Revenue in Cancer Molecular Biomarkers Business (2015-2020) (Million US$)
Table 104. Becton Recent Development
Table 105. Diadexus Company Details
Table 106. Diadexus Business Overview
Table 107. Diadexus Product
Table 108. Diadexus Revenue in Cancer Molecular Biomarkers Business (2015-2020) (Million US$)
Table 109. Diadexus Recent Development
Table 110. Abbott Laboratories Business Overview
Table 111. Abbott Laboratories Product
Table 112. Abbott Laboratories Company Details
Table 113. Abbott Laboratories Revenue in Cancer Molecular Biomarkers Business (2015-2020) (Million US$)
Table 114. Abbott Laboratories Recent Development
Table 115. Affymetrix Company Details
Table 116. Affymetrix Business Overview
Table 117. Affymetrix Product
Table 118. Affymetrix Revenue in Cancer Molecular Biomarkers Business (2015-2020) (Million US$)
Table 119. Affymetrix Recent Development
Table 120. Clarient Company Details
Table 121. Clarient Business Overview
Table 122. Clarient Product
Table 123. Clarient Revenue in Cancer Molecular Biomarkers Business (2015-2020) (Million US$)
Table 124. Clarient Recent Development
Table 125. Biomoda Company Details
Table 126. Biomoda Business Overview
Table 127. Biomoda Product
Table 128. Biomoda Revenue in Cancer Molecular Biomarkers Business (2015-2020) (Million US$)
Table 129. Biomoda Recent Development
Table 130. Beckman Coulter Company Details
Table 131. Beckman Coulter Business Overview
Table 132. Beckman Coulter Product
Table 133. Beckman Coulter Revenue in Cancer Molecular Biomarkers Business (2015-2020) (Million US$)
Table 134. Beckman Coulter Recent Development
Table 135. Dickinson Company Details
Table 136. Dickinson Business Overview
Table 137. Dickinson Product
Table 138. Dickinson Revenue in Cancer Molecular Biomarkers Business (2015-2020) (Million US$)
Table 139. Dickinson Recent Development
Table 140. Research Programs/Design for This Report
Table 141. Key Data Information from Secondary Sources
Table 142. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Cancer Molecular Biomarkers Market Share by Type: 2020 VS 2026
Figure 2. Genetic Methods Features
Figure 3. Protein Methods Features
Figure 4. Imaging Features
Figure 5. Global Cancer Molecular Biomarkers Market Share by Application: 2020 VS 2026
Figure 6. Pharmaceutical Companies Case Studies
Figure 7. Medical Laboratory Case Studies
Figure 8. Hospital Case Studies
Figure 9. Cancer Molecular Biomarkers Report Years Considered
Figure 10. Global Cancer Molecular Biomarkers Market Size YoY Growth 2015-2026 (US$ Million)
Figure 11. Global Cancer Molecular Biomarkers Market Share by Regions: 2020 VS 2026
Figure 12. Global Cancer Molecular Biomarkers Market Share by Regions (2021-2026)
Figure 13. Porter's Five Forces Analysis
Figure 14. Global Cancer Molecular Biomarkers Market Share by Players in 2019
Figure 15. Global Top Cancer Molecular Biomarkers Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Cancer Molecular Biomarkers as of 2019
Figure 16. The Top 10 and 5 Players Market Share by Cancer Molecular Biomarkers Revenue in 2019
Figure 17. North America Cancer Molecular Biomarkers Market Size YoY Growth (2015-2020) (Million US$)
Figure 18. Europe Cancer Molecular Biomarkers Market Size YoY Growth (2015-2020) (Million US$)
Figure 19. China Cancer Molecular Biomarkers Market Size YoY Growth (2015-2020) (Million US$)
Figure 20. Japan Cancer Molecular Biomarkers Market Size YoY Growth (2015-2020) (Million US$)
Figure 21. Southeast Asia Cancer Molecular Biomarkers Market Size YoY Growth (2015-2020) (Million US$)
Figure 22. India Cancer Molecular Biomarkers Market Size YoY Growth (2015-2020) (Million US$)
Figure 23. Central & South America Cancer Molecular Biomarkers Market Size YoY Growth (2015-2020) (Million US$)
Figure 24. Bottom-up and Top-down Approaches for This Report
Figure 25. Data Triangulation
Figure 26. Key Executives Interviewed
血清がんバイオマーカーの世界市場（～2026年） Serum biomarkers are proteins generally detected in urine, blood, and other bodily fluids produced by malignant cells or in reaction to presence/absence of malignant cells. Preferably, biomarkers should have at least one or more than one of the following properties: prompt detection of cancer within…- 予測バイオマーカーの世界市場（～2026年） Predictive biomarkers help to optimize therapy decisions, as they provide information on the likelihood of response to a given chemotherapeutic. The predictive biomarkers market is expected to register a fast growth over the forecast period owing to the increase in the prevalence rate of cancer. Mar…
- ゲノミクスバイオマーカーの世界市場（～2026年） A measurable DNA and/or RNA characteristic is an indicator of normal biologic processes, pathogenic processes, and/or response to a therapeutic or other interventions. A genomic biomarker can be used for measuring the expression, function, and regulation of a gene. These biomarkers have characterist…
- 心臓バイオマーカーの世界市場（～2026年） Cardiovascular diseases are leading cause of morbidity and mortality globally. Biomarkers are generally used as an indicator forparticular diseases such as rheumatic and congenital heart diseases and cardiac arrhythmia. Cardiac biomarkers are measurable and quantifiable biological parameters. These …
- EPOバイオマーカーの世界市場（～2026年） Erythropoietin (EPO) is a hormone that is produced from the kidney inside the human body. EPO biomarkers are used to increase the growth of red blood cells in the body by stimulating the bone marrow. Major factors contributing to the growth of the global EPO biomarkers market include increasing sede…